Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.50 |
| ▸ | CES1 | P23141 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29571616 | 1.00 | CES2 (0.50) | CES2CES1MEN1CYP1A2KMT2A | |
| Hydrochloric Acid SCHEMBL20491499 | 0.98 | CES2 (0.49) | CES2CES1MEN1CYP1A2KMT2A | |
| SCHEMBL25907635 | 0.85 | CES2 (0.50) | CES2CES1MEN1CYP1A2KMT2A | |
| SCHEMBL1115202 | 0.85 | CES2 (0.50) | CES2CES1CYP3A4IDO1TDO2 | |
| SCHEMBL8073211 | 0.83 | MEN1 (0.59) | MEN1CYP1A2KMT2ACYP3A4GRM1 | |
| SCHEMBL7395512 | 0.81 | GRM1 (0.65) | CES2CES1MEN1CYP1A2KMT2A | |
| Hydrochloric Acid SCHEMBL2894693 | 0.81 | MEN1 (0.57) | MEN1CYP1A2KMT2ACYP3A4GRM1 | |
| SCHEMBL12737974 | 0.81 | MEN1 (0.49) | MEN1CYP1A2KMT2ACYP3A4GRM1 | |
| SCHEMBL25932983 | 0.81 | IDO1 (0.44) | CES2CES1CYP3A4IDO1TDO2 | |
| SCHEMBL22023199 | 0.80 | GRM1 (0.42) | MEN1CYP1A2KMT2ACYP3A4GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117326961-B | Green synthesis method of non-surafaxin intermediate | 安徽峆一药业股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117326961-B | Green synthesis method of non-surafaxin intermediate | 安徽峆一药业股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117326961-A | Green synthesis method of non-surafaxin intermediate | 安徽峆一药业股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-117326961-A | Green synthesis method of non-surafaxin intermediate | 安徽峆一药业股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-11851434-B2 | Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230373954-A1 | NOVEL ACID SECRETION INHIBITOR AND USE THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-23 | — | — | US | disclosed |
| US-11767311-B2 | Acid secretion inhibitor and use thereof | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-09-26 | — | — | US | disclosed |
| EP-4219448-A1 | METHOD FOR PREPARING A SYNTHETIC INTERMEDIATE OF A 4-METHOXYPYRROLE DERIVATIVE | Daewoong Pharmaceutical Co., Ltd. (KR) | 2023-08-02 | — | — | EP | disclosed |
| EP-4219448-A1 | METHOD FOR PREPARING A SYNTHETIC INTERMEDIATE OF A 4-METHOXYPYRROLE DERIVATIVE | Daewoong Pharmaceutical Co., Ltd. (KR) | 2023-08-02 | — | — | EP | disclosed |
| US-20230192650-A1 | NOVEL ACID SECRETION INHIBITOR AND USE THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-06-22 | — | — | US | disclosed |
| US-20200181080-A1 | METHOD FOR PREPARING INTERMEDIATE OF 4-METHOXYPYRROLE DERIVATIVE | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2020-06-11 | — | — | US | disclosed |
| EP-3642181-A1 | METHOD FOR PREPARING INTERMEDIATE OF 4-METHOXYPYRROLE DERIVATIVE | Daewoong Pharmaceutical Co., Ltd. (KR) | 2020-04-29 | — | — | EP | disclosed |
| EP-3630722-A1 | METHOD FOR PREPARING INTERMEDIATE OF 4-METHOXYPYRROLE DERIVATIVE | Daewoong Pharmaceutical Co., Ltd. (KR) | 2020-04-08 | — | — | EP | disclosed |
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC | 2020-02-20 | — | — | US | disclosed |
| WO-2018236153-A1 | METHOD FOR PREPARING INTERMEDIATE OF 4-METHOXYPYRROLE DERIVATIVE | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2018-12-27 | — | — | WO | disclosed |
| WO-2018221971-A1 | METHOD FOR PREPARING INTERMEDIATE OF 4-METHOXYPYRROLE DERIVATIVE | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2018-12-06 | — | — | WO | disclosed |
| WO-2018136661-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-07-26 | — | — | WO | disclosed |
| US-20110059940-A1 | 2-Aryl Glycinamide Derivatives | BRISTOL- MYERS SQUIBB COMPANY | 2011-03-10 | — | — | US | disclosed |
| EP-2278878-A1 | 2-ARYL GLYCINAMIDE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009137657-A1 | 2-ARYL GLYCINAMIDE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767311-B2 | Acid secretion inhibitor and use thereof | SLC10A2, SLC10A1, ASIC1 | CES2 1621/4885CES1 502/4885MEN1 1938/4885 |
| US-20230373954-A1 | NOVEL ACID SECRETION INHIBITOR AND USE THEREOF | SLC10A2, SLC10A1, ASIC1 | CES2 1727/4885CES1 479/4885MEN1 2339/4885 |
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, ROR1 | CES2 4282/4885CES1 4089/4885MEN1 1084/4885 |
| US-11851434-B2 | Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors | RET, BRAF, ROR1 | CES2 4282/4885CES1 4089/4885MEN1 1084/4885 |
| US-20110059940-A1 | 2-Aryl Glycinamide Derivatives | IAPP, APP, BACE1 | CES2 2407/4885CES1 1809/4885MEN1 2644/4885 |
| US-20200181080-A1 | METHOD FOR PREPARING INTERMEDIATE OF 4-METHOXYPYRROLE DERIVATIVE | MLN, TYK2, TH | CES2 2274/4885CES1 4491/4885MEN1 587/4885 |
| US-20230192650-A1 | NOVEL ACID SECRETION INHIBITOR AND USE THEREOF | SLC10A2, SLC10A1, ASIC1 | CES2 1727/4885CES1 479/4885MEN1 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.